Ultromics receives Breakthrough Device Designation for AI cardiac amyloidosis tool and more digital health briefs
UK-based Ultromics announced it received FDA Breakthrough Device Designation for an AI tool that aims to detect cardiac amyloidosis. The platform, called EchoGo Amyloidosis, analyzes echocardiograms to find signs of the condition, where the protein amyloid builds up in the heart and limits function. Though the designation isn’t a marketing approval from the FDA, it […]